10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul
A decade ago, then GSK R&D chief Moncef Slaoui proudly unveiled a $100 million plan to build a big neurosciences research group in Shanghai. The project called for hiring 1,000 scientists in six years as the pharma giant sought to make major advances on Alzheimer’s, Parkinson’s and MS.
“We don’t want to give them the crumbs,” Slaoui told the Financial Times, pointedly rejecting the notion that cheap labor had led them to the move. “It’s about different science. We will link our fate to their fate. Within five to ten years we will be moving from ‘made in China’ to ‘discovered in China’.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
